Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) Receives Consensus Recommendation of “Hold” from Brokerages

Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) has been given an average recommendation of “Hold” by the twelve analysts that are covering the stock, MarketBeat reports. One research analyst has rated the stock with a sell recommendation, seven have assigned a hold recommendation and four have given a buy recommendation to the company. The average 12 month target price among brokers that have issued a report on the stock in the last year is $6.64.

MRVI has been the topic of a number of analyst reports. Robert W. Baird dropped their price target on shares of Maravai LifeSciences from $3.00 to $2.00 and set a “neutral” rating on the stock in a research note on Tuesday, May 13th. Bank of America dropped their price target on shares of Maravai LifeSciences from $9.00 to $8.00 and set a “buy” rating on the stock in a research note on Monday, March 3rd. Stifel Nicolaus set a $5.00 price target on shares of Maravai LifeSciences in a research note on Friday, March 21st. Morgan Stanley dropped their price target on shares of Maravai LifeSciences from $7.00 to $5.00 and set an “equal weight” rating on the stock in a research note on Tuesday, March 25th. Finally, UBS Group dropped their price target on shares of Maravai LifeSciences from $8.00 to $2.50 and set a “neutral” rating on the stock in a research note on Friday, March 21st.

Maravai LifeSciences Stock Up 10.6%

Shares of Maravai LifeSciences stock opened at $2.40 on Friday. Maravai LifeSciences has a 12-month low of $1.67 and a 12-month high of $11.50. The company has a market cap of $611.18 million, a P/E ratio of -1.46 and a beta of 0.19. The company has a current ratio of 10.74, a quick ratio of 9.94 and a debt-to-equity ratio of 0.89. The company’s fifty day simple moving average is $2.09 and its two-hundred day simple moving average is $3.96.

Maravai LifeSciences (NASDAQ:MRVI) last announced its earnings results on Monday, May 12th. The company reported ($0.08) EPS for the quarter, missing analysts’ consensus estimates of ($0.07) by ($0.01). Maravai LifeSciences had a negative net margin of 81.13% and a negative return on equity of 6.61%. The business had revenue of $46.85 million for the quarter, compared to the consensus estimate of $44.01 million. The business’s revenue was down 26.9% on a year-over-year basis. Research analysts anticipate that Maravai LifeSciences will post -0.24 EPS for the current year.

Institutional Investors Weigh In On Maravai LifeSciences

Several hedge funds and other institutional investors have recently made changes to their positions in MRVI. Performa Ltd US LLC increased its position in shares of Maravai LifeSciences by 614.3% during the 4th quarter. Performa Ltd US LLC now owns 5,000 shares of the company’s stock valued at $27,000 after purchasing an additional 4,300 shares during the last quarter. EntryPoint Capital LLC purchased a new stake in shares of Maravai LifeSciences during the 1st quarter valued at about $32,000. Teacher Retirement System of Texas purchased a new stake in shares of Maravai LifeSciences during the 1st quarter valued at about $37,000. Aigen Investment Management LP purchased a new stake in shares of Maravai LifeSciences during the 1st quarter valued at about $37,000. Finally, FNY Investment Advisers LLC increased its position in shares of Maravai LifeSciences by 600.0% during the 4th quarter. FNY Investment Advisers LLC now owns 7,000 shares of the company’s stock valued at $38,000 after purchasing an additional 6,000 shares during the last quarter. Hedge funds and other institutional investors own 50.25% of the company’s stock.

Maravai LifeSciences Company Profile

Maravai LifeSciences Holdings, Inc, a life sciences company, provides products to enable the development of drug therapies, diagnostics, novel vaccines, and support research on human diseases worldwide. The company’s products address the key phases of biopharmaceutical development and include nucleic acids for diagnostic and therapeutic applications, antibody-based products to detect impurities during the production of biopharmaceutical products, and products to detect the expression of proteins in tissues of various species.